Group 1 - The core focus of the market this week is on companies with overseas expansion concepts, with a significant interest in Daikin Heavy Industries, which received over 200 institutional inquiries [1][2] - Since the beginning of the year, nearly 500 listed companies have disclosed institutional investor research records, with Daikin Heavy Industries leading with 209 inquiries [1][2] - The top ten A-share companies by the number of institutional inquiries include Daikin Heavy Industries, Xiangyu Medical, and Haitai Ruisheng, indicating a strong interest in sectors such as heavy electrical equipment and medical devices [1][2] Group 2 - Daikin Heavy Industries is focusing on its bidding progress in the European and other overseas markets for offshore wind projects, with significant expectations for Germany, Japan, the Netherlands, and Poland [3] - The company has a high market share in the German offshore wind foundation sector and has secured a port in Cuxhaven for localized services [3] - Xiangyu Medical is also exploring overseas business opportunities, prioritizing products that have obtained FDA and CE certifications for international markets [3] Group 3 - Haitai Ruisheng has integrated a data annotation base in Southeast Asia, which is expected to contribute millions in revenue by 2025, marking a new phase in its overseas delivery capabilities [4] - Over 800 institutions have conducted research on A-share listed companies this week, with CITIC Securities and Guotai Junan Securities leading in the number of inquiries [4] - Fund companies such as Bosera Fund and GF Fund have shown strong interest in Daikin Heavy Industries, indicating a robust demand for insights into the company [5] Group 4 - Daikin Heavy Industries has forecasted a net profit of 1.05 billion to 1.2 billion yuan for 2025, representing a year-on-year growth of 121.58% to 153.23% [5] - The company attributes its growth to a rapid increase in the number and value of projects delivered in the overseas offshore wind market, along with higher product construction standards [6] - The provision of systematic services for offshore wind equipment construction, transportation, and localized installation has further enhanced the company's profitability [6]

Group 1 - The core focus of the market this week is on companies involved in overseas expansion, with significant interest in Daikin Heavy Industries, which received inquiries from over 200 institutions [1][2] - A total of nearly 500 companies have disclosed institutional investor research records since the beginning of the year, with Daikin Heavy Industries leading at 209 inquiries [1][2] - The top ten A-share companies by the number of research institutions include Daikin Heavy Industries, Xiangyu Medical, and Haitan Ruisheng, indicating a strong interest in sectors such as heavy electrical equipment and medical devices [1][2] Group 2 - Daikin Heavy Industries is focusing on the European and other overseas markets for offshore wind bidding in 2026, with significant projects expected in Germany, Japan, the Netherlands, and Poland [3] - The company has a high market share in the German offshore wind foundation sector and has secured a port in Cuxhaven for localized services [3] - Xiangyu Medical is also exploring overseas business, prioritizing products with FDA and CE certifications for markets along the Belt and Road, and considering local manufacturing or acquisitions [3] Group 3 - Haitan Ruisheng plans to establish a second localized delivery base in Southeast Asia by 2026, which will enhance its capacity to handle large orders from major clients [4] - Over 800 institutions have conducted research on A-share companies this week, with notable interest from CITIC Securities and Guotai Junan Securities [4] - Fund companies such as Bosera and GF Fund have shown strong interest in Daikin Heavy Industries, indicating a positive outlook on the company's performance [5] Group 4 - Daikin Heavy Industries has forecasted a net profit of 1.05 billion to 1.2 billion yuan for 2025, representing a year-on-year growth of 121.58% to 153.23% [5][6] - The company's growth is attributed to a rapid increase in project deliveries and higher product construction standards, which enhance value [6] - The provision of systematic services for offshore wind equipment construction, transportation, and localized installation is expected to further boost the company's profitability [6]

Group 1 - Institutional research enthusiasm remains high, with nearly 500 companies disclosing investor research records this year, and Dajin Heavy Industry receiving the most attention with 209 institutional inquiries [3][4] - The top ten A-share companies by the number of institutional inquiries include Dajin Heavy Industry, Xiangyu Medical, and Haitai Ruisheng, indicating a strong interest in sectors such as heavy electrical equipment and medical devices [4][6] - The focus on overseas expansion is a key theme, with Dajin Heavy Industry highlighting its expectations for offshore wind project tenders in Europe and other markets, particularly in Germany, Japan, and Poland [7][8] Group 2 - Dajin Heavy Industry anticipates significant growth in its overseas offshore wind market, projecting a net profit of 1.05 billion to 1.2 billion yuan for 2025, representing a year-on-year increase of 121.58% to 153.23% [12][13] - The company attributes its profit growth to an increase in the number and value of projects delivered in the offshore wind sector, as well as enhanced service offerings that include construction, transportation, and localized installation [13] - Other companies, such as Xiangyu Medical, are also focusing on overseas strategies, prioritizing products with FDA and CE certifications for international markets, and exploring opportunities in cross-border e-commerce [7][8]

Market Performance - On January 23, the A-share market indices collectively rose, with the Shanghai Composite Index increasing by 0.33% to 4136.16 points, the Shenzhen Component Index rising by 0.79% to 14439.66 points, and the ChiNext Index up by 0.63% to 3349.5 points [1]. Sector Performance - The sectors that performed well included HIT batteries, space-based internet, and space station concepts, while sectors such as computing power, CPO concepts, and natural gas experienced declines [1]. - HIT batteries saw a net inflow of 9.39%, while the computing power sector faced a net outflow of 214.3 billion, reflecting a decrease of 2.32% [2]. Fund Manager Changes - On January 23, there were 36 fund manager changes across various funds, with 22 funds announcing departures of fund managers, involving 8 individuals [3]. - In the past 30 days, a total of 569 fund managers have left their positions, with 6 leaving due to job changes and 2 for personal reasons [3]. New Fund Managers - On January 23, 55 funds announced new fund manager appointments, involving 28 new managers. Notably, Sun Di from GF Fund has a total fund asset scale of 72.47 billion and has achieved a return of 224.66% on the GF High-end Manufacturing Stock A fund over 2 years and 131 days [5]. Fund Research Activity - In the past month (December 24 to January 23), Huaxia Fund conducted the most company research, engaging with 53 listed companies, followed by Bosera Fund with 49 and Southern Fund with 42 [7]. - The chemical products industry was the most researched sector, with 193 instances, followed by the automotive parts industry with 173 [7]. Individual Stock Research - The most researched stock in the past month was Dajin Heavy Industry, with 67 fund management companies participating in the research. This company specializes in offshore wind power equipment [9]. - In the last week (January 16 to January 23), Dajin Heavy Industry remained the top company researched, followed by NaiPu Mining Machinery and Runfeng Co., Ltd. [9].

基金经理是一只基金产品最核心的成员，能决定一只基金的投资方向、投资策略以及投资风格，基金经理出色的择时选股 能力和调研预测能力是基金业绩的有力保证，所以基金经理是投资者在选择基金产品时的重要依据。基金经理的变动很大 程度上会影响到基金产品未来的表现，是一个需要特别关注的信息。1.22日共有16位基金经理发生任职变动。 根据巨灵统计的数据，近30天（12.23-1.22）共有595只基金产品的基金经理发生离职。其中今天（1.22）日有18只基金产 品发布基金经理离职公告，涉及8名基金经理。从变动原因上来看，有5位基金经理是由于工作变动而从管理的7只基金产品 中离职。有1位基金经理是由于产品到期而从管理的1只基金产品中离职。有1位基金经理是由于辞职而从管理的2只基金产 品中离职。有1位基金经理是由于个人原因而从管理的8只基金产品中离职。 | | | 基金代码 | 公告日期 | | | | | --- | --- | --- | --- | --- | --- | --- | | ■開切/し | | 005607 | 2026/1/22 | 20: | | | | | 华宝中证500增强C | 005608 | 2 ...

Group 1 - Institutional research activity decreased this week, with a reduction in the number of companies being surveyed, but top stocks received increased attention [1] - Xiangyu Medical (688626) was favored by 208 institutions, focusing on rehabilitation medical devices, with strong growth potential driven by aging population and health awareness [1] - The company has a solid capital structure rated BBB, indicating better financial stability compared to most listed companies, but faces challenges in operational efficiency and asset quality [1] Group 2 - SWOT analysis for Xiangyu Medical shows strengths in capital structure, but weaknesses in operational efficiency and scale, with significant room for improvement in multiple dimensions [2][3] - Opportunities exist for Xiangyu Medical to enhance operational efficiency and scale, with potential growth in market channels and cost control [2] - Threats include a notable decline in core capabilities, particularly in operational efficiency and profitability, indicating increased operational pressure [3] Group 3 - Lio Group (002131) was surveyed by 40 institutions, focusing on its dual business model of mechanical manufacturing and digital marketing, with strong interest in its growth potential in emerging sectors [5] - The company has strong scale strength rated AA, indicating significant competitive advantages, but faces challenges in cash flow and debt repayment capabilities [6] - SWOT analysis reveals Lio Group's strengths in asset quality and scale, but weaknesses in cash flow and development capabilities, with opportunities for improvement in emerging markets [7][8] Group 4 - Weichuang Electric (688698) was the subject of a survey by 35 institutions, focusing on its core products in industrial automation and its competitive advantages in the market [10] - The company has strong profitability and asset quality ratings, but faces challenges in cash flow and debt repayment capabilities [11] - SWOT analysis indicates strengths in profitability and operational efficiency, but weaknesses in cash flow and capital structure, with opportunities for growth in high-demand sectors [12][13] Group 5 - Light Optoelectronics (688150) was surveyed by 34 institutions, focusing on its core products in OLED materials and its competitive position in the market [15] - The company has strong debt repayment capabilities and a solid capital structure, but faces challenges in scale and operational efficiency [16] - SWOT analysis shows strengths in financial stability and profitability, but weaknesses in scale and operational efficiency, with significant opportunities for growth in emerging markets [17][18] Group 6 - Yunnan Ge Industry (002428) was surveyed by 32 institutions, focusing on its complete germanium industry chain and its strategic position in the market [20] - The company has a strong development capability rating, but faces significant challenges in cash flow, profitability, and operational efficiency [21] - SWOT analysis indicates strengths in development capability, but weaknesses in scale and financial stability, with opportunities for growth in commercial aerospace and semiconductor sectors [22][23]

Core Insights - The article highlights the advancements in brain-computer interface (BCI) technology, particularly in rehabilitation medical devices, as demonstrated by Xiangyu Medical in Anyang, Henan province [1][2]. Company Overview - Xiangyu Medical is a leading enterprise in China's rehabilitation medical device industry, focusing on integrating cutting-edge technologies like BCI into their products [1]. - The company has successfully adapted 27 rehabilitation devices to BCI technology as of December 31, 2025, with a goal to reach nearly 100 devices by the end of 2026 [3]. Technology and Innovation - The BCI technology showcased includes non-invasive methods that convert brain signals into device commands, allowing users to control rehabilitation equipment through thought alone [1][2]. - The company emphasizes the safety and convenience of non-invasive BCI compared to invasive methods, which require surgical implantation and carry higher risks and costs [2]. Industry Context - The domestic BCI industry is experiencing rapid technological advancements and expanding application scenarios, with both invasive and non-invasive approaches being developed [2]. - Xiangyu Medical collaborates with 62 upstream and downstream companies within the rehabilitation equipment industry park in Neihuang County, creating a comprehensive industrial chain that supports research, manufacturing, and service [3]. Future Goals - The company aims to establish a complete brain-controlled rehabilitation ecosystem by integrating mainstream rehabilitation devices with BCI technology over the next five years [3]. - Xiangyu Medical is committed to accelerating the clinical application of BCI products to benefit patients, leveraging its extensive experience in industry-academia-research collaboration [3].

Core Insights - The article highlights the advancements in brain-computer interface (BCI) technology, particularly in rehabilitation medical devices, as demonstrated by Xiangyu Medical Equipment Co., Ltd. [1][2] Company Overview - Xiangyu Medical is a leading enterprise in China's rehabilitation medical device industry, focusing on innovative technologies such as brain-computer interfaces [1]. - The company has successfully adapted 27 rehabilitation devices to BCI technology as of December 31, 2025, with a goal to achieve nearly 100 BCI-enabled rehabilitation devices by the end of 2026 [3]. Technology Development - The BCI industry in China is experiencing rapid technological iteration and expanding application scenarios, with both invasive and non-invasive technologies being developed [2]. - Non-invasive BCI technology, which uses devices like EEG caps to collect brain signals, is considered safer and more convenient for large-scale promotion in rehabilitation and health management [2]. Industry Collaboration - Xiangyu Medical collaborates with 62 upstream and downstream companies within the rehabilitation equipment industrial park in Neihuang County, creating a complete industrial chain that includes research, manufacturing, and service [3]. - The company aims to accelerate the transformation of innovative results into clinical applications through collaborative innovation and established market channels [3].

脑机接口市场发展情况如何？未来的产业发展方向是什么？翔宇医疗如何紧抓市场机遇？带着这些问 题，《证券日报》记者走进翔宇医疗，与公司董事长何永正展开探讨与交流。 脑机接口赋能主动康复 脑机接口作为康复领域的创新技术，正引领着康复行业从"被动康复"转向"主动康复"。该技术通过实时 捕捉脑电信号并解码，驱动外部设备对大脑进行针对性刺激，形成"感知－响应－强化"的神经发育闭 环，让康复训练更高效、更精准。 本报记者 肖艳青 作为连接大脑与外部设备的颠覆性技术，脑机接口正被全球科技界视为重构人机交互范式的核心方向。 在政策支持、技术突破与资本涌入等多重因素驱动下，脑机接口产业发展提速，应用前景已从医疗康复 延伸至消费电子等多元场景，展现出巨大的市场潜力。 河南翔宇医疗设备股份有限公司（以下简称"翔宇医疗"）凭借在康复医疗领域的技术积淀，自2015年起 便开始布局脑机接口及类脑研究。目前该公司率先实现脑机接口技术的临床转化，相关产品已进入国内 超600家三级甲等医院，覆盖神经康复、运动功能重建等核心领域，成为国内脑机接口医疗应用的领军 企业。 "主动康复效果强于被动康复。"何永正表示，"脑机接口技术是一种让大脑持续深度参 ...

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]